Vincent Angotti is joining AcelRx Pharmaceuticals (NASDAQ: [[ticker:ACRX]]) as the Redwood City, CA-based pain drug developer’s CEO. Agnotti was most recently CEO of XenoPort. His experience also includes roles at Reliant Pharmaceuticals and Novartis (NYSE: [[ticker:NVS]]). Angotti will start at AcelRx on March 6.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
